TETANUS AND DIPHTHERIA TOXOIDS ADSORBED Rx
Generic Name and Formulations:
Tetanus and diphtheria toxoids; aluminum adsorbed; susp for IM inj; contains residual formaldehyde, thimerosal (trace); latex-free.
Merck & Co., Inc.
Indications for TETANUS AND DIPHTHERIA TOXOIDS ADSORBED:
Tetanus and diphtheria immunization in patients ≥7yrs.
Adults and Children:
<7yrs: not recommended. ≥7yrs: Give IM in deltoid muscle. Previously unvaccinated: three 0.5mL doses at elected date, then 4–8 weeks after first dose, and 6–12 months after second dose. Give booster dose at 11–12yrs of age if last dose of tetanus and diphtheria toxoid-containing vaccine was given ≥5yrs ago. Other: give booster every 10yrs. Diphtheria and tetanus prophylaxis: see full labeling.
Anaphylaxis associated with a previous dose.
Guillain-Barre syndrome within 6 weeks of previous tetanus toxoid vaccine. Previous Arthus-type hypersensitivity reaction: not recommended until ≥10yrs after prior dose of tetanus toxoid-containing vaccine. Immunodeficiency. Have epinephrine (1:1000) available. Elderly. Pregnancy (Cat.C). Nursing mothers.
Concomitant vaccines: see full labeling. Immunosuppressants (eg, radiation, chemotherapy, high-dose steroids): may get suboptimal response.
Local reactions (eg, erythema, tenderness), dizziness, headache, myalgia, fever; rare: neurological disorders.
Formerly known under the brand name Decavac.
Single-dose vials (0.5mL)—10
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|